Amicus Therapeutics (NASDAQ: FOLD) has recently received a number of price target changes and ratings updates:

  • 10/10/2017 – Amicus Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $16.00 price target on the stock. According to Zacks, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. “
  • 10/6/2017 – Amicus Therapeutics had its “neutral” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $17.00 price target on the stock.
  • 10/5/2017 – Amicus Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $18.50 price target on the stock, up previously from $16.50.
  • 10/4/2017 – Amicus Therapeutics had its price target raised by analysts at Bank of America Corporation from $15.00 to $20.00. They now have a “buy” rating on the stock.
  • 10/4/2017 – Amicus Therapeutics had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $20.00 price target on the stock, up previously from $17.00.
  • 10/4/2017 – Amicus Therapeutics had its “overweight” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/4/2017 – Amicus Therapeutics had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $18.00 price target on the stock, up previously from $16.00.
  • 9/25/2017 – Amicus Therapeutics had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $16.00 price target on the stock.
  • 9/16/2017 – Amicus Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $17.00 price target on the stock, down previously from $18.00.
  • 9/14/2017 – Amicus Therapeutics had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $18.00 price target on the stock, up previously from $16.00.
  • 9/13/2017 – Amicus Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $16.50 price target on the stock, down previously from $17.50.
  • 8/17/2017 – Amicus Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/14/2017 – Amicus Therapeutics had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $16.00 price target on the stock.

Shares of Amicus Therapeutics, Inc. (FOLD) traded down 0.14% during mid-day trading on Thursday, reaching $14.25. The company’s stock had a trading volume of 3,191,733 shares. The company has a 50-day moving average of $14.31 and a 200-day moving average of $10.80. Amicus Therapeutics, Inc. has a 12 month low of $4.41 and a 12 month high of $16.60. The company’s market cap is $2.35 billion.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The business had revenue of $7.16 million during the quarter, compared to the consensus estimate of $6.96 million. During the same quarter last year, the firm earned ($0.40) earnings per share. Equities research analysts forecast that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current fiscal year.

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.